Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
Rhea-AI Summary
Cocrystal Pharma (NASDAQ: COCP) has announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 12:00 p.m. Eastern time.
The event will feature a live Q&A session, and qualified investors can request one-on-one meetings with management through the conference platform. A video webcast of the presentation will be available within 48 hours on both the Cocrystal website and Channelchek, where it will remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, COCP gained 0.70%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m. (noon) Eastern time (9:00 a.m. Pacific time). Investors and interested individuals can register for the conference here. Questions from the audience during the live fireside chat will be welcomed.
Registered, qualified investors can request one-on-one meetings with Cocrystal management through the conference registration platform.
A video webcast of the presentation will be available within approximately 48 hours following the event on the Cocrystal website, and as part of a complete catalog of presentations available on Channelchek, the investor portal created by Noble. The webcast will be archived on the Company’s website and on Channelchek.com for 90 days following the event.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
When is Cocrystal Pharma (COCP) presenting at the Noble Capital Markets Conference 2025?
How can investors access Cocrystal Pharma's (COCP) Noble Conference presentation?
How long will Cocrystal Pharma's (COCP) Noble Conference presentation be available for viewing?
Can investors meet with Cocrystal Pharma's (COCP) management during the Noble Conference?
